Spark Therapeutics (NASDAQ:ONCE), a gene therapy company based in Philadelphia, USA, has announced a three year vision to expand the company’s gene therapy portfolio and… Read More »Spark Therapeutics announces plans to have 10 gene therapy clinical programs in place by 2018, including up to three ophthalmic indications
Bayer AG (Xetra: BAYN), Leverkusen, Germany and CRISPR Therapeutics AG, Basel, Switzerland have announced the creation of a 50/50 joint venture “to discover, develop and… Read More »Bayer AG and CRISPR Therapeutics AG announce joint venture targeting blindness, heart disease and blood disorders.
GenSight Biologics Inc., Paris, France, are set to progress with gene therapy clinical trials following clearance from the U.S. Food and Drug Administration (FDA) for… Read More »GenSight Biologics progresses gene therapy treatment for Leber’s Hereditary Optic Neuropathy
Applied Genetic Technologies Corp. (NASDAQ: AGTC), a gene therapy company based in Gainesville, Florida, has announced the receipt of orphan drug designation from the U.S.… Read More »AGTC Inc receives US FDA orphan designation of experimental gene therapy treatment for achromatopsia
Spark Therapeutics (NASDAQ:ONCE), a gene therapy company based in Philadelphia, USA, has announced additional efficacy results of the “first randomized, controlled phase 3 trial of… Read More »Spark Therapeutics announces additional efficacy outcomes from first randomised US trial in gene therapy
The London Project to Cure Blindness, launched by Professor Pete Coffey, Professor of Cellular Therapies at the Institute of Ophthalmology, University College London, has announced… Read More »The London Project, supported by Pfizer Inc. initiate UK phase I stem cell trial for treatment of AMD
Ocata Therapeutics Inc. (NASDAQ:OCAT), based in Marlborough, Massachusetts, and formerly known as Advanced Cell Technology Inc., or ACT, have announced the enrollment of their first… Read More »Ocata Therapeutics Inc., announces enrolment of first patient in embryonic stem cell derived therapy treatment for dry age-related macular degeneration
RetroSense Therapeutics LLC, a private company based in Ann Arbor, Michigan, has announced receipt of clearance from the FDA to initiate a first-in-human study of… Read More »RetroSense Therapeutics announces IND application for novel optogenetic RP therapy
Santhera Pharmaceuticals (SIX: SANN), a Swiss based company focused on the treatment of mitochondrial and neuromuscular disease, has announced the receipt of marketing authorization for… Read More »Santhera Pharmaceuticals (Switzerland) announces first approval by the European Commission for a Leber’s Hereditary Optic Neuropathy (LHON) treatment
StemCells Inc., (NASDAQ: STEM), based in Newark, California, has announced the dosing of a first patient with purified human neural stem cells directed at the… Read More »StemCells Inc., transplants first patient in Phase II clinical trial for dry age-related macular degeneration